SCYNEXIS (NASDAQ: SCYX) and Teligent (NASDAQ:TLGT) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their risk, dividends, profitability, analyst recommendations, valuation, institutional ownership and earnings.

Analyst Ratings

This is a breakdown of current recommendations and price targets for SCYNEXIS and Teligent, as reported by MarketBeat.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
SCYNEXIS 0 1 5 0 2.83
Teligent 0 2 1 0 2.33

SCYNEXIS presently has a consensus target price of $9.50, indicating a potential upside of 326.01%. Teligent has a consensus target price of $7.00, indicating a potential upside of 78.57%. Given SCYNEXIS’s stronger consensus rating and higher possible upside, equities research analysts plainly believe SCYNEXIS is more favorable than Teligent.

Risk and Volatility

SCYNEXIS has a beta of 0.35, meaning that its stock price is 65% less volatile than the S&P 500. Comparatively, Teligent has a beta of 1.34, meaning that its stock price is 34% more volatile than the S&P 500.

Profitability

This table compares SCYNEXIS and Teligent’s net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
SCYNEXIS -8,569.46% -64.12% -37.45%
Teligent -16.95% -6.51% -1.92%

Valuation and Earnings

This table compares SCYNEXIS and Teligent’s revenue, earnings per share (EPS) and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
SCYNEXIS $260,000.00 244.96 -$29.98 million N/A N/A
Teligent $66.88 million 3.13 -$11.98 million ($0.22) -17.82

Teligent has higher revenue and earnings than SCYNEXIS.

Insider & Institutional Ownership

31.3% of SCYNEXIS shares are held by institutional investors. Comparatively, 70.8% of Teligent shares are held by institutional investors. 4.0% of SCYNEXIS shares are held by company insiders. Comparatively, 22.6% of Teligent shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Summary

Teligent beats SCYNEXIS on 8 of the 12 factors compared between the two stocks.

SCYNEXIS Company Profile

SCYNEXIS, Inc. is engaged in the discovery, development and commercialization of anti-infectives. The Company is developing its lead product candidate, SCY-078, as an oral and intravenous (IV) drug for the treatment of several fungal infections, including serious invasive fungal infections. SCY-078 is a structurally distinct glucan synthase inhibitor that has been shown to be effective in vitro and in vivo in animal studies against a range of Candida and Aspergillus species, including drug-resistant strains. The Company also conducts additional in vitro and in vivo studies to further characterize the spectrum of activity of SCY-078. The Company has completed multiple Phase I studies with the oral formulation of SCY-078 and is conducting its first Phase I study with the IV formulation of SCY-078. The Company has also developed a platform for cyclophilin inhibitors, which has two clinical stage compounds, such as SCY-635 and SCY-641.

Teligent Company Profile

Teligent, Inc. is a specialty generic pharmaceutical company. Under the Company’s own label, it markets and sells generic injectable pharmaceutical products in the United States and Canada. In the United States it marketed 16 generic topical pharmaceutical products and four branded generic pharmaceutical products, as of December 31, 2016. It provides development, formulation and manufacturing services to the pharmaceutical, over-the-counter (OTC) and cosmetic industries. It focuses on developing, manufacturing and marketing a portfolio of generic pharmaceutical products under its own label in topical, injectable, complex and ophthalmic dosage forms, and managing its contract manufacturing and formulation services business. Its pipeline included 34 Abbreviated New Drug Application(ANDAs) filed with the United States Food and Drug Administration (FDA) for additional pharmaceutical products, as of December 31, 2016.

Receive News & Ratings for SCYNEXIS Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for SCYNEXIS Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.